Sagimet Biosciences Inc.
SGMT
$10.55
$1.2713.69%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -34.34% | 41.41% | 40.94% | 11.70% | -27.94% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 163.33% | 78.07% | 33.86% | 91.95% | 40.02% |
| Change in Net Operating Assets | -587.20% | -88.70% | -217.23% | 111.67% | -108.46% |
| Cash from Operations | -21.95% | 40.76% | -7.34% | 47.98% | -61.54% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -80.74% | 199.33% | 45.77% | -87.98% | 82.32% |
| Cash from Investing | -80.74% | 199.33% | 45.77% | -87.98% | 82.32% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 17,518,800.00% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 16,438,800.00% | -- | -- | -- | 103.70% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 677.36% | 114.43% | 315.08% | 48.11% | 72.30% |